Fig. 1 | Cellular & Molecular Immunology

Fig. 1

From: Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates

Fig. 1

Experimental design. Male Indian rhesus macaques were immunized with one (Day 0) or two (Days 0 and 28) intramuscular (IM) doses of 15 µg of CoVLP (formulated or not with the adjuvant CpG 1018 or AS03) or control. Animal immunization and safety evaluation before challenge were performed at the New Iberia Research Center. Approximately 1 week before the challenge, the animals were transferred to the Tulane National Primate Research Center for the second part of the protocol, which included viral infection and safety and protection evaluations. Animals were challenged with SARS-CoV-2 USA-WA1/2020 on Day 28 (animals immunized with one dose) or Day 57 (animals immunized with two doses) and sacrificed 6 or 20 days after the challenge

Back to article page